MARKET

JAGX

JAGX

Jaguar Health Inc
NASDAQ
0.3907
-0.0083
-2.08%
Opening 14:32 04/09 EDT
OPEN
0.3980
PREV CLOSE
0.3990
HIGH
0.3980
LOW
0.3700
VOLUME
580.40K
TURNOVER
--
52 WEEK HIGH
15.48
52 WEEK LOW
0.3130
MARKET CAP
4.85M
P/E (TTM)
-0.0007
1D
5D
1M
3M
1Y
5Y
1D
Jaguar Health completes effectiveness study of crofelemer tablets
TipRanks · 1d ago
Jaguar Health Completes Its Ongoing Effectiveness Study Of Crofelemer Delayed-Release Tablets For Chemotherapy-Induced Diarrhea In Dogs
Benzinga · 1d ago
Jaguar Health completes dog trial to support full FDA approval for Canalevia-CA1
Reuters · 1d ago
Jaguar Health reports Q4 results
Seeking Alpha · 1d ago
Jaguar Health reports FY25 EPS ($24.27) vs. ($130.69) last year
TipRanks · 2d ago
Jaguar Health FY25 net loss widens 28.2% to $53.6 million; revenue slips 1.5% to $11.5 million
Reuters · 2d ago
Jaguar Health FY25 net loss widens 37.6% to $54 million
Reuters · 2d ago
Weekly Report: what happened at JAGX last week (0330-0403)?
Weekly Report · 3d ago
More
About JAGX
Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health.

Webull offers Jaguar Health Inc stock information, including NASDAQ: JAGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, JAGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading JAGX stock methods without spending real money on the virtual paper trading platform.